INAB Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
IN8bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.17 |
| 52 Week High | US$1.74 |
| 52 Week Low | US$0.13 |
| Beta | 0.24 |
| 1 Month Change | 12.18% |
| 3 Month Change | -33.22% |
| 1 Year Change | -83.02% |
| 3 Year Change | -94.50% |
| 5 Year Change | n/a |
| Change since IPO | -98.30% |
Recent News & Updates
Recent updates
IN8bio (NASDAQ:INAB) Will Have To Spend Its Cash Wisely
Aug 06
We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate
Apr 03Companies Like IN8bio (NASDAQ:INAB) Could Be Quite Risky
Nov 04Is IN8bio (NASDAQ:INAB) In A Good Position To Invest In Growth?
Jan 26Here's Why We're Watching IN8bio's (NASDAQ:INAB) Cash Burn Situation
Oct 12IN8bio gains 53% as H.C. Wainwright initiates with Buy
Aug 30IN8bio raises additional funds from underwriter of stock offering
Aug 19IN8bio prices $10.25M stock offering
Aug 12We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate
Jun 04IN8bio (NASDAQ:INAB) Is In A Good Position To Deliver On Growth Plans
Feb 13IPO Update: IN8bio Aims For Downsized IPO
Jul 29Shareholder Returns
| INAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.8% | 1.9% | 2.8% |
| 1Y | -83.0% | -6.9% | 9.3% |
Return vs Industry: INAB underperformed the US Biotechs industry which returned -6.9% over the past year.
Return vs Market: INAB underperformed the US Market which returned 9.3% over the past year.
Price Volatility
| INAB volatility | |
|---|---|
| INAB Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 11.8% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: INAB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INAB's weekly volatility has decreased from 19% to 11% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 18 | William Ho | in8bio.com |
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer.
IN8bio, Inc. Fundamentals Summary
| INAB fundamental statistics | |
|---|---|
| Market cap | US$13.77m |
| Earnings (TTM) | -US$30.44m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs INAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INAB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.44m |
| Earnings | -US$30.44m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did INAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 16:24 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IN8bio, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Soumit Roy | JonesTrading Institutional Services, LLC |